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1. Introduction:  
Influenza A virus (IAV) is a seasonal epidemic virus which infects between 10-15% of the 
global population each year [1, 2].  Infection results in illness typically lasting between 5 and 
15 days, characterised by respiratory distress, fever, headache and myalgia. In at-risk patients 
such as the elderly, infants and the immunocompromised, IAV can cause significant 
morbidity resulting hospitalisation and death [3]. IAV exists in several different subtypes that 
can be classified on the basis of the 18 variants of the hemagglutinin (HA) and 11 variants of 
the neuraminidase (NA) proteins expressed by the virus. Further minor variation in these 
proteins can be used to differentiate strains of IAV. In immune-competent individuals IAV 
infection stimulates an immune response that confers lasting protection that is strain specific. 
However, immunity to one strain rarely confers protection against other strains and there is 
even less cross-protection between sub-types. Thus, minor seasonal variations in IAV 
antigenic composition (antigenic drift) can result in individuals experiencing repeated bouts 
of influenza due to different strains, while changes in the prevalent seasonal IAV subtype 
(antigenic shift) poses an even greater immunological challenge.  In addition to seasonal 
epidemics, novel strains of the virus arise periodically which can cause global influenza 
pandemics associated with increased mortality in all patient groups [4].  Current influenza 
vaccines are designed to protect against the predominant circulating strains of IAV in a given 
year, identified through epidemiological surveillance. The vaccine efficacy relies on accurate 
prediction of the circulating seasonal strains and these recommendations are reviewed and 
updated annually. However, there is often a mismatch between the predicted vaccine target 
strains and the prevalent strain that causes a seasonal epidemic resulting in low vaccine 
efficacy [5, 6]. Furthermore, current vaccines are unlikely to protect against newly emergent 
pandemic strains that may arise following recombination between strains such as avian and 
human IAV [7, 8].  Current IAV vaccines target immunodominant regions of the virus that 
are subject to particularly high mutation rates and so protection is frequently short-lived since 
variant strains emerge which escape immune memory and recognition. To overcome this 
variation an alternative strategy is to target highly conserved regions of the virus, mutation of 
which may severely compromise virus viability. Despite the high variability of proteins such 
as hemagglutinin and neuraminidase, the major targets of existing vaccine strategies, 
previous work has shown that some protein domains within IAV are highly conserved 
between different subtypes, strains and clades [9-11].  These conserved domains represent 
potential targets for a universal IAV vaccine which could generate broad immunity against 
many strains of IAV and thus remove the need to use epidemiological surveillance to predict 
the likely prevalent strains. Moreover, such a vaccine may have the advantage of conferring 
longer lasting immunity, obviating the need for annual vaccinations, because a vaccine based 
on conserved antigens will not be rendered obsolete by mutations in the variable parts of 
IAV. The protein targets within IAV that show a good degree of conservation include 
nucleoprotein (NP), matrix protein 1 and 2, some epitopes of neuraminidase (NA), and the 
stalk domains of hemagglutinin (HA) [12-14].  Previous attempts to exploit these antigens in 
vaccines have had only moderate success because usually the conserved domains are poorly 
immunogenic in the context of trivalent or quadrivalent inactivated vaccines. This may be 
because they have not been presented in the correct conformation or because the 
immunological context of presentation was not sufficient to generate protective immunity 
[15-19]. We have attempted to harness the immunogenic properties of hepatitis B core 
protein VLP to enhance the immunogenicity of conserved IAV antigens that fail to elicit 
effective immune responses through natural infection or split virus vaccines.  We have 
adapted hepatitis B tandem core [20] sub-units to generate a virus-like particle (VLP) vaccine 
incorporating 3 variants of the Matrix protein 2 ectodomain (M2e) and a conserved antigen 
from group 1 HA-stalk to create an IAV vaccine candidate.  
Tandem core (TC) is composed of two hepatitis B core molecules linked by a poly-glycine-
serine linker that confers stability and facilitates assembly of multiple TC subunits into a 
virus-like particle. Each TC has two independent major insertion regions (MIRs) each of 
which can accommodate exogenous antigens in the correct conformation for antigenic 
recognition, and within the immunogenic context of a VLP [21-23]. In our vaccine, the first 
major insertion region (MIR) has been engineered to incorporate a HA-stalk structural 
antigen from H1N1 corresponding to an alpha-helix within HA2 domain of hemagglutinin 
stalk, sometimes referred to as long alpha-helix (LAH) [24]. The sequence encoded in the 
MIR is based on an extended sequence from the A/Luxembourg/46/09 pandemic IAV strain. 
The second major insertion site in our VLP incorporates three variants of the influenza matrix 
protein 2 conserved ectodomain (M2e) as a triplet sequence insert based on the predominant 
variants found in H1N1, H5N1 and H11N9 subtypes. Thus the final vaccine candidate, 
named Tandiflu1, bears a total of 4 conserved IAV antigens contained within a single VLP 
(Fig.1).  The conservation, cross-protection and functionality of these IAV antigens has been 
amply characterised [11, 15, 18, 25-28] but to our knowledge, their incorporation into a 
single recombinant protein vaccine has not been developed or tested previously. In this study 
we report the expression of Tandiflu1 VLP in Escherichia coli, followed by immunisation of 
mice to assess its immunogenicity and the evaluation of vaccine efficacy in a mouse model of 
live influenza virus infection.   
 
2. Materials and methods:  
2.1 VLP construct design  
Tandem core (TC) is based on the wild type Hepatitis B core (HBc) protein (Fig.1A) that self-
assembles into a virus-like particle (VLP).  In one TC, two HBc monomers are molecularly 
linked together to yield a more stable dimer that spontaneously assembles to form a VLP 
[20]. Each dimer bears two major insertion sites. TC VLP without any inserts (empty core) 
was used as a control not containing IAV antigens (Fig.1B).  The Tandiflu1 VLP 
incorporates an antigen from the hemagglutinin stalk domain (HA-stalk) based on the 
pandemic H1N1 A/Luxembourg/43/2009 influenza virus sequence [29] inserted into the first 
major insertion region (MIR1). This intermediate construct was expressed and tested to 
determine the immunogenicity of HA-stalk as a single insert VLP; referred to in the text as 
HA-stalk VLP (Fig.1C).  The second insertion region of Tandiflu1 contains a triplet antigen 
insert, corresponding to three different variants of a conserved region of the matrix-protein 2 
ectodomain that are found in the majority of IAV strains.  To determine the immunogenicity 
of this triplet insert as a single MIR insert VLP, the intermediate construct was generated 
containing the triple M2e antigen insert in MIR2 with the other MIR1 left empty, referred to 
in the text as 3M2e VLP (Fig.1D). The complete Tandiflu1 capsomere contains the HA-stalk 
antigen in MIR1 and the triplet M2e antigen in MIR2 (Fig.1E). Tandiflu1 assembles into a 
VLP comprised of 90-120 individual capsomeres. The full genomic sequences for Tandiflu1 
inclusive of the IAV inserts has been previously published in patent application 
PCT/GB2015/053699 with publication number WO2016087863 A1  [30].  
2.2 Cloning and Expression  
 The constructs described above (TC VLP, 3M2e VLP, HA-stalk VLP and Tandiflu1) were 
synthesised via GeneArt (Life Technologies) and included the restriction sites XbaI and XhoI 
at the 5’ and 3’ ends respectively. Using these restriction sites, the constructs were cloned 
into the pET28b(+) plasmid (Novagen #69865) and used to transform E. coli DH5 alpha cells 
(NEB #C2987H). Positive clones were identified via colony PCR and sequencing and used 
for the extraction of plasmids which were then used to transform E.coli BL21 cells (NEB 
#C2527I) for VLP expression. Bacterial expression was performed by culturing E.coli BL21 
(DE3) clones in Luria-Bertani broth containing 50 g/ml of kanamycin at 37C at 250 rpm in 
an orbital shaking incubator up to an optical density (OD 600) of 0.6. Induction was triggered 
by adding 1 mM Isopropyl β-D-1-thiogalactopyranoside and incubating the culture for 17 
Hrs. at 12C in a shaking incubator set to 250 rpm.  
 
2.3 Purification and Analysis of VLP 
 Briefly E.coli cells were harvested from liquid culture by centrifugation at 15,000 g for 30 
min. in a bench-top centrifuge. The cell pellet was then re-suspended in lysis buffer (20 mM 
Tris, 5 mM 1,4-dithiothreitol, 2 mM 4-benzenesulfonyl fluoride hydrochloride, 125 U/g 
Benzonase, pH 8) at a density of 0.125 g wet weight/ml. Cells were then disrupted by 
micronisation (APV Gaulin Micron Lab40 homogeniser, 1200 bar, 3 passes), followed by 
detergent extraction (0.05% Tween 20, 1 Hr. on ice) and clarification by ultra-centrifugation 
(20,000 g, 30 min., 4C). VLP were further solubilised by addition of an equal volume of 20 
mM TRIS, 5 mM EDTA, 2 M urea buffer (pH 8), and concentrated 40-fold using tangential 
flow filtration with a 1 MDa nominal molecular weight limit, Pellicon-XL 50 cassette 
(Millipore #PXB050A50). The resulting concentrate was then applied to 2 subsequent gel-
filtration chromatography columns; a Sepharose CL-4B column (GE #17015001) was run in 
a buffer consisting of 20 mM Tris pH 8.4, 5 mM EDTA, 1 M urea. The void volume 
containing VLPs and larger components was subjected to a second round of size exclusion 
chromatography using a Sephacryl S-1000 SF resin (GE #17047601) (in 20 mM Tris pH 8.4, 
5 mM EDTA). The fractions containing VLP were collected and analysed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), Western Blot and electron 
microscopy to confirm the presence and identity of the VLPs. For SDS-PAGE, samples were 
heated to 95C for 5 min. in Laemmli buffer and loaded on Mini Protean Any kD tgx gels 
(BIO-RAD #4569035) together with the Precision Plus Protein molecular weight marker 
(BIO-RAD #161-0363), and run at 160 V for 40 mins. After protein transfer onto a 0.45 m 
nitrocellulose membrane using standard methods, the presence of protein of interest was 
detected using anti-HBc antibody - clone 10E11 (Abcam #Ab8639)- in combination with 
goat anti-mouse IgG-Peroxidase (Sigma #A4416) and Super Signal chemiluminescent 
substrate (Fisher #10743105).  
 
2.4 Immunisation and infection  
Groups of at least 5 female BALB/c mice (Envigo, U.K.) 6-8 weeks old were immunised 
with 15 g of purified VLP mixed with 20 l of Imject Alum (Thermo Scientific #77161) 
and 20 l of Sigma Adjuvant System (Sigma #S6322) made up to a volume of 100 l with 
sterile saline solution.  Primary immunisation was delivered intra-peritoneally (i.p.), 
secondary and tertiary immunisations were delivered sub-cutaneously (s.c.). Immunisations 
were performed 1 week apart. 3 weeks after the final immunisation mice were infected intra-
nasally (i.n) with 5x MLD50 of influenza A virus (A/PR 8/34 H1N1).  MLD50 was 
calculated using the Reed and Muench method [31] and translated as TCID50 by the 
Pearman & Kärber algorithm as described in Hierholzer & Killington Virology Methods 
Manual [32]   where 1x MLD50= 103.11 TCID50. Weight loss and clinical score was 
monitored daily after infection with a maximum weight loss limit of 20% in compliance with 
U.K. Home Office approved animal protocols under licence PPL 70/7376.  
2.5 Antibody titres   
Tail bleeds were performed to check seroconversion at weekly intervals following 
immunisation. Detection of anti-HA or anti-M2e antibodies was performed by Enzyme-
linked immunosorbent assay (ELISA). Briefly, 96-well Nunc Maxisorp plates (Sigma 
#M9410-1CS) were coated with 1g/ml recombinant hemagglutinin (rHA Life 
Technologies)) from influenza virus (subtype as indicated in the text) in carbonate bi-
carbonate buffer, or 6.25 g/ml of the M2e consensus peptide sequence 
MSLLTEVETPIRNEWGCRCNGSSD-OH (Activotec) in 1 M NaCl buffer. Coated plates 
were washed 3x with PBS-Tween20 0.05% (PBST) and blocked with 10% skimmed milk 
solution (Sigma #1.15363.0500) for 1 Hr. at 37C. Pooled serum from 5 mice per group was 
diluted in 2.5% milk was added to the test wells and plates were incubated at 37C for 1 Hr. 
then washed 3x as before. Goat-anti-mouse IgG –peroxidase secondary antibody (Ab) was 
added at 1/2500 dilution (Sigma #12-349) and incubated at 37C for 1 Hr. then washed 3x as 
before.  3,3′,5,5′-Tetramethylbenzidine substrate (Sigma# T0440) was added to each well for 
20 min. and reaction was stopped with 1 M H2SO4. Anti-M2e monoclonal antibody 14C2 
(Abcam #ab5416) was used a positive control for M2 peptide detection. Serum from mice 
inoculated with a sub-lethal titre of A/PR 8/34 H1N1 virus (PR8 immune +) was used as a 
positive control for rHA detection. Absorbance (Abs) at 450 nm with a 630 nm correction 
was read using the SpectraMAX 190 plate reader (Molecular Devices, USA).  All wells were 
run in duplicate with at least 3 dilution repeats. 
2.6 Cell binding assays  
Madin Darby canine kidney (MDCK.2) cells (ATCC #CRL-2936) were cultured in Roswell 
Park Memorial Institute medium and infected at a multiplicity of infection of 2, with H1N1 
(A/PR 8/34) for 2-3 days. Infected cells were then harvested and fixed, together with 
uninfected controls. Cells were then incubated with serum from Tandiflu1 immunised mice 
for 30 min. at room temperature. After 5x washes with PBST, a secondary goat-anti mouse 
IgG- FITC (Abcam #ab7064) conjugate was used to stain the cells for 30 min. at room 
temperature on an orbital shaker with gentle rotation.  The ability of Tandiflu1 serum to bind 
infected cells was then determined by Flow cytometry using the Epics XL-MCL (Beckman 
Coulter) flow cytometer by gating on cells which were positive for bound IgG on FL1 FITC 
(Fluorescein isothiocyanate) green fluorescence channel.  
2.7 Passive serum transfer   
100 l of serum collected from mice immunised with Tandiflu1 (or serum collected from 
control mice immunised with empty core VLP containing no IAV insert) was injected i.p. 
into naïve BALB/c female mice 6-8 weeks old. On the same day, these mice were infected 
with 3 x MLD50 of influenza A virus (A/PR 8/34 H1N1) virus intra-nasally. Three days post-
infection a second identical serum injection was given to both groups of mice. Weight loss 
and clinical scores were monitored daily after infection. Animals were euthanized if they 
exhibited extreme distress or weight loss exceeding 20% from baseline weight following 
approved Home Office U.K.  animal protocols under licence PPL70/7376.  
 
2.8 Infected cells in the lung  
The degree of IAV infection was determined by measuring the relative proportion of lung 
cells expressing influenza nuclear protein (NP) in lung homogenate from infected and control 
mice. Briefly the lungs from infected mice (or naïve controls) were homogenized to single 
cell suspension by pressing them through a 100m nylon mesh strainer and incubated with 
red blood cell lysis buffer (Roche #11814389001) for 5 minutes at 4C. Cell viability was 
assessed using Live/Dead stain (Thermofisher L23102), with monoclonal mouse anti-
influenza A virus nucleoprotein antibody conjugated to FITC (Abcam #ab20921) to 
determine infection. The percentage of live lung cells infected with IAV was determined by 
using flow cytometry (BC Epics XL-MCL flow cytometer) by gating on live cells expressing 
nucleoprotein on the FL1 FITC channel. We determined the percentage of lung cells 
expressing influenza NP; and therefore infected with influenza A virus.   
2.9 Statistical Analysis 
 Prism version 7.03 (Graphpad) was used to perform statistical analysis. For Kaplan-Meier 
survival plots the Gehan-Breslow Wilcoxon test was used. Welch’s t-test was applied to 
compare averages of group body mass between infected and control groups using a 5% 
threshold for significance. The Mann-Whitney test was used for rank comparison of viral 
infectivity between 2 groups adopting a 5% threshold for significance.  
 
 
3. Results:  
3.1 Tandem core carrying multiple influenza conserved domains forms a virus-like particle 
(VLP)  
The TC VLP containing a HA-stalk and three M2e inserts (Tandiflu1) was expressed in E. 
coli and purified using a combination of tangential flow filtration and gel filtration 
chromatography. Western blot analysis shows a band at 68.8 kDa corresponding to the full 
length Tandiflu1 recombinant protein (Appendix1. D).  Size exclusion chromatography 
(SEC) was used to select larger protein complexes between 3 to 6 MDa found in the eluted 
fractions, and electron micrographs confirmed the presence of purified VLP conforming to a 
30-40 nm diameter size (Appendix1 Fig.1). This purified material was used for all subsequent 
immunisation experiments in mice.  
 
3.2 Immunisation with Tandiflu1 VLP generates antibodies to conserved influenza A 
antigens  
In addition to generating the final Tandiflu1 construct with multiple inserts (Fig.1e) we first 
created two single insert VLP with IAV antigens inserted into only one of the two TC MIRs; 
HA-stalk VLP and 3M2 VLP (Fig.1c and 1d respectively). Mice vaccinated with the HA-
stalk VLP generated polyclonal antibodies that bind recombinant HA (H1), and similarly, 
mice vaccinated with 3M2 VLP generated an anti-M2e specific IgG response (Fig.2A/B). 
Mice vaccinated with Tandiflu1 generated polyclonal antibodies against both HA-stalk and 
M2e simultaneously (Fig.2A/B). Seroconversion to both antigens (M2 and HA) in response 
to vaccination with Tandiflu1 was confirmed independently by the Luxembourg Institute of 
Health, using Tandiflu1 manufactured at iQur using a classical two-week interval 
immunisation schedule and MF59 adjuvant (Appendix 2).  
We tested the ability of anti-Tandiflu1 antibodies to bind MDCK cells infected with influenza 
virus by flow cytometric analysis. We found that the sera from Tandiflu1 vaccinated mice 
can bind influenza antigens expressed by cells infected with H1N1 virus, and no binding was 
observed to uninfected cells (Fig.3A). Binding of HA or M2 expressed by MDCK confirms 
that the antibodies generated by vaccination can bind the antigenic targets in the context of 
influenza infected cells. This is important since many antibody mediated effector 
mechanisms rely on targeting infected cells instead of direct virus neutralisation, especially 
when the HA globular head domain is not a vaccine component.  
In order to assess the cross-reactivity of the anti-HA antibodies induced by Tandiflu1, the 
serum from immunised mice was tested against a panel of recombinant HA from various 
subtypes by ELISA. Figure 3B shows that there is binding to all of group 1 hemagglutinins 
tested (H1, H5, H9, H11 and H16), but not group 2 hemagglutinins (H3, H7), demonstrating 
broad cross-reactivity of Tandiflu1 antibodies to HA within Group 1 but not Group 2 IAV 
strains. Positive binding to various group 1 hemagglutinins confirms the conservation of the 
selected antigen vaccine target across multiple subtypes.  
 
3.3 Vaccination with Tandiflu1 VLP confers 100% survival in challenge with H1N1 IAV  
Mice were immunised with either Tandiflu1 or the single insert HA-stalk VLP, 3M2 VLP or 
with the negative control empty TC VLP containing no influenza inserts (Fig.1).  Mice 
immunised three times with Tandiflu1 showed minimal signs of disease as measured by 
weight loss after viral challenge with H1N1 IAV, whereas the mice in the negative control 
group reached the lethal severity limit (Fig.4A). By day 7 post-infection survival in the 
control groups was 0%, compared to 100% in the Tandiflu1 immunised group (Fig.4B).  In 
addition, mice vaccinated with the simpler VLPs containing only HA-stalk or M2 inserts also 
showed increased group survival (Fig.4B).  The HA-stalk VLP vaccinated group provides 
further evidence of a cross-protective immune response since the VLP antigen was derived 
from the H1N1 2009 pandemic strain HA-stalk sequence template and the live challenge 
administered was a heterologous A/PR8/1934 H1N1 virus. Further confirmation of efficacy 
was obtained when Tandiflu1 immunised mice were also 100% protected from a challenge 
with H1N1 A/Luxembourg/43/2009 pandemic strain, in a protection experiment carried out 
independently at the Luxembourg Institute of Health (Appendix 2).  
 
3.4 Tandiflu1 immunised mice have protective antibodies and reduced viral titres  
Mice immunised with Tandiflu1 showed reduced signs of infection and increased survival, 
but vaccination did not induce sterilising immunity. This is consistent with previously 
published data which show HA-stalk and M2e immunity permits infection but protects 
against severe manifestations of influenza [18, 25, 28, 33].  In order to investigate the 
mechanism by which Tandiflu1 confers protection against IAV we harvested the lungs of 
immunised mice 3 days after viral challenge with PR/8 H1N1 virus. The vaccinated group 
presented with a decreased percentage of IAV infected lung cells equivalent to a 6-fold 
decrease in viral infection compared to sham vaccine controls (Fig.5).  
In order to determine whether passive serum transfer from Tandiflu1 immunised mice was 
sufficient to confer protection we injected 100l of Tandiflu1 immune serum into naïve mice 
at day 0 and 3 post-infection. All the mice that received the anti-Tandiflu1 serum survived 
challenge with a lethal dose of H1N1 compared to 40% of control animals. Immunized mice 
exhibited less weight loss during H1N1 viral challenge, whereas recipients of control serum 
had diminished survival and increased weight loss (Fig.6).  
 
4. Discussion:  
In the face of the deficiencies of current seasonal influenza vaccines that confer strain-
specific immunity a universal influenza vaccine is highly desirable and, as a result, has been 
the focus of significant research effort. Over the past two decades research groups have 
endeavoured to identify the conserved and functional protein targets within influenza virus 
that could make this a reality. There has been previous moderate success using purified single 
or conjugated antigens, but as data accumulate it is becoming clear that a broader multi-target 
approach may be more effective than a vaccine directed at a single target.  Here we present 
an IAV vaccine candidate (Tandiflu1) that combines four conserved antigen sequences from 
two different influenza proteins on a single VLP display platform, representing the first 
successful insertion of different antigens into dual MIR sites for a HBc based VLP.  The 
tandem core VLP platform was chosen because hepatitis B virus core is a well-studied 
protein that has been shown to be a safe and well-tolerated vaccine subunit in human trials 
(NCT00819013). Additionally, the well-documented propensity of hepatitis B virus core to 
confer immunogenicity to associated antigens is required when targeting epitopes with low 
natural immunogenicity [22, 23].  
Tandiflu1 is the first vaccine application of the tandem core VLP, and immunisation with 
Tandiflu1 leads to simultaneous generation of antibodies to the M2 ectodomain as well as 
cross-reactive antibodies to group 1 hemagglutinin stalk. Matrix protein 2 ectodomain has 
been extensively characterised as a potential immunogen in universal influenza vaccines. De 
Filette et. al and others have previously shown that complete survival can be achieved with 
M2e vaccination administered in various forms [27, 28, 34]. Yet, mice effectively protected 
from lethal infection still experienced significant weight loss and exhibited signs of influenza.  
This indicates that immune protection targeting the M2e alone is not sufficient to prevent 
symptomatic influenza. Similarly, the LAH domain within the HA-stalk has long been known 
to be a conserved domain of IAV [35]. Wang and colleagues characterised this epitope and 
found that antibodies to this stalk domain are protective in the face of lethal IAV challenge 
[36]. Since then, many groups have tried to target this region with mixed success. While 
some groups demonstrated broad cross-protection others found only modest protection levels 
to the homologous viral strain [24, 37-40].  However, to our knowledge, a single vaccine 
platform which simultaneously targets both HA-stalk and M2 protein antigens has not 
previously been produced or tested. We showed that a VLP containing the M2e triplet 
antigen was sufficient for 100% group survival but targeting two conserved antigens 
simultaneously increases the probability of broad IAV coverage and decreases the likelihood 
of escape variants arising from a single gene mutation.  
Our data suggest that immunisation with Tandiflu1 combining three M2e variants and HA-
stalk antigen results in significant protection against influenza mortality. We have 
demonstrated that the tandem core platform allows the integration of several functional 
vaccine antigens into a single VLP, with implications for the generation of a multi-valent 
immune response, as well as an impact on lowering cost of production by producing multiple 
subunit antigens by a single process.  
 The precise immune mechanisms for M2 and LAH vaccines remain a source of discussion.  
Several groups have shown that administration of anti-M2e antibodies before or during 
infection can confer protection against IAV associated illness [41, 42].  Equally, others have 
shown that anti-LAH antibody injections are sufficient to protect mice from IAV infection 
[36]. Antibodies which bind the HA stalk have been shown to mediate protection by Fc 
receptor mediated neutrophil degranulation and phagocytosis, and NK-cell antibody-
dependent cellular cytotoxicity (ADCC) [43, 44]. The protection conferred by Tandiflu1 
vaccination is also mediated by antibody dependent mechanisms since protection was 
observed during passive serum transfer experiments, although the full role of cellular 
immunity requires further investigation. For antibodies which target M2 ectodomain, Saelens 
and colleagues showed that immune complement and ADCC play a small role, but most of 
the protective activity derives from antibody dependent cell-mediated phagocytosis (ADCP) 
[45]. This is mediated by alveolar macrophages and is transduced through their Fc receptors. 
The effector mechanism is dependent on anti-M2e antibodies binding influenza infected cells 
that are subsequently destroyed by phagocytic cells. We showed that serum from Tandiflu1 
immunised mice can bind IAV infected MDCK cells, thus antibody mediated effector 
functions targeting infected cells may explain the reduction in influenza infected lung cells at 
day 3 we observed. Future work will attempt to address the specific mechanisms of 
protection. 
 The anti-HA antibodies failed to recognise HA from group 2 viruses, this is not unexpected 
since the template sequence for the Tandiflu1 HA insert is from a group 1 H1N1 subtype. In 
the future, we plan to design a second VLP that incorporates HA stalk inserts from group 2 
influenza A subtypes and possibly influenza B, towards the development of a multi-valent 
universal influenza vaccine candidate.  Tandiflu1 has been generated at laboratory scale and 
shown to be bioactive in vivo, however, as Tandiflu1 particles tended to aggregate and 
exhibited limited stability some optimisation will be required before this vaccine can be 
manufactured and formulated as a viable vaccine for human or animal use.  
 
5. Conclusion:  
The prospect of a universal influenza vaccine seems to be within reach and in recent years 
many potential candidates have been proposed. Guided by the recent success of commercial 
and experimental VLP vaccines which have been shown to be safe and effective, we have 
combined four well documented influenza universal antigen targets within a single VLP 
vaccine. The development of tandem core allowing larger inserts to be carried at multiple 
sites in chimeric virus-like particles [20] has enabled us to harness the immunogenic 
properties of hepatitis B virus core as a vaccine platform[22, 23]. We present an IAV vaccine 
candidate that generates cross-reactive and protective antibody responses to multiple 
conserved influenza A virus antigens simultaneously. Vaccination with this VLP (Tandiflu1) 
results in 100% protection from two H1N1 strains in a mouse model of influenza infection.   
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